Form 144 Vir Biotechnology For: 25 February

Vir Biotechnology filed a Form 144 on February 25, 2026, indicating an intention to sell restricted securities representing 27.73% of the company's stock, though the specific reasons for the sale remain unspecified in the public record. The biotechnology firm's filing comes amid a turbulent week in financial markets, where AMD shares surged 14% following a Meta AI partnership deal, while Bitcoin plummeted, wiping out 50% of its value from its October record high during a session low. Wall Street managed to close higher on a tech rebound ahead of the State of the Union address, with software stocks particularly benefiting from Anthropic partnerships that eased concerns about AI disruption. The Form 144 filing by Vir Biotechnology suggests potential significant share activity from insiders or large shareholders, as this type of document is typically required when an insider plans to sell restricted securities that were acquired through means other than a public offering.